Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Licensing and Other Arrangements - Takeda (Details)

v3.24.2.u1
Acquisitions, Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 212 Months Ended
Nov. 01, 2006
Feb. 28, 2009
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Dec. 31, 2023
Licensing and other arrangements                
Revenue from contracts with customers     $ 5,025 $ 1,125 $ 6,025 $ 1,125    
Takeda Pharmaceutical Company Limited | Collaboration Agreement                
Licensing and other arrangements                
Maximum milestone payments entitled to receive     16,000   16,000   $ 16,000  
Revenue from contracts with customers             3,000  
Contract assets     0   0   0 $ 0
Contract liabilities     0   0   0 0
Capitalized contract costs     $ 0   $ 0   $ 0 $ 0
Takeda Pharmaceutical Company Limited | Collaboration Agreement | TAK-079                
Licensing and other arrangements                
Maximum milestone payments entitled to receive $ 19,000              
Percentage of royalty on sales 4.00%              
Minimum period eligible to receive royalties 13 years 6 months              
Royalty payment period from the first commercial sale of each royalty-bearing discovery product 12 years              
Takeda Pharmaceutical Company Limited | Collaboration Agreement | Other antibodies                
Licensing and other arrangements                
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300            
Minimum period eligible to receive royalties   10 years